(Q45368315)

English

Genotypic resistance profile of hepatitis B virus (HBV) in a large cohort of nucleos(t)ide analogue-experienced Chinese patients with chronic HBV infection.

scientific article published on 6 September 2010

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21392168%20AND%20SRC:MED&resulttype=core&format=json

25 January 2020

Genotypic resistance profile of hepatitis B virus (HBV) in a large cohort of nucleos(t)ide analogue-experienced Chinese patients with chronic HBV infection (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21392168%20AND%20SRC:MED&resulttype=core&format=json

25 January 2020

Hepatitis B virus

1 reference

based on heuristic

inferred from title

14

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21392168%20AND%20SRC:MED&resulttype=core&format=json

25 January 2020

author name string

Y Liu

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21392168%20AND%20SRC:MED&resulttype=core&format=json

25 January 2020

C Wang

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21392168%20AND%20SRC:MED&resulttype=core&format=json

25 January 2020

Y Zhong

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21392168%20AND%20SRC:MED&resulttype=core&format=json

25 January 2020

X Li

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21392168%20AND%20SRC:MED&resulttype=core&format=json

25 January 2020

J Dai

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21392168%20AND%20SRC:MED&resulttype=core&format=json

25 January 2020

X Ren

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21392168%20AND%20SRC:MED&resulttype=core&format=json

25 January 2020

Z Xu

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21392168%20AND%20SRC:MED&resulttype=core&format=json

25 January 2020

L Li

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21392168%20AND%20SRC:MED&resulttype=core&format=json

25 January 2020

Z Yao

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21392168%20AND%20SRC:MED&resulttype=core&format=json

25 January 2020

D Ji

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21392168%20AND%20SRC:MED&resulttype=core&format=json

25 January 2020

L Wang

11

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21392168%20AND%20SRC:MED&resulttype=core&format=json

25 January 2020

L Zhang

12

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21392168%20AND%20SRC:MED&resulttype=core&format=json

25 January 2020

V W-S Wong

13

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21392168%20AND%20SRC:MED&resulttype=core&format=json

25 January 2020

D Xu

15

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21392168%20AND%20SRC:MED&resulttype=core&format=json

25 January 2020

publication date

6 September 2010

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21392168%20AND%20SRC:MED&resulttype=core&format=json

25 January 2020

Journal of Viral Hepatitis

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21392168%20AND%20SRC:MED&resulttype=core&format=json

25 January 2020

18

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21392168%20AND%20SRC:MED&resulttype=core&format=json

25 January 2020

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21392168%20AND%20SRC:MED&resulttype=core&format=json

25 January 2020

e29-39

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21392168%20AND%20SRC:MED&resulttype=core&format=json

25 January 2020

Virologic monitoring of hepatitis B virus therapy in clinical trials and practice: recommendations for a standardized approach

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2010.01360.X

21 January 2018

EASL Clinical Practice Guidelines: management of chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2010.01360.X

21 January 2018

Therapeutic strategies in the management of patients with chronic hepatitis B virus infection.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2010.01360.X

21 January 2018

Hepatitis B Virus Infection

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2010.01360.X

21 January 2018

Hepatitis B: reflections on the current approach to antiviral therapy.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2010.01360.X

21 January 2018

Hepatitis B virus resistance to nucleos(t)ide analogues.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2010.01360.X

21 January 2018

Antiviral-resistant hepatitis B virus: can we prevent this monster from growing?

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2010.01360.X

21 January 2018

Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2010.01360.X

21 January 2018

The polymerase L528M mutation cooperates with nucleotide binding-site mutations, increasing hepatitis B virus replication and drug resistance

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2010.01360.X

21 January 2018

The hepatitis B virus polymerase mutation rtV173L is selected during lamivudine therapy and enhances viral replication in vitro.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2010.01360.X

21 January 2018

Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2010.01360.X

21 January 2018

Variant of hepatitis B virus with primary resistance to adefovir

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2010.01360.X

21 January 2018

Adefovir and lamivudine in combination compared with adefovir monotherapy in HBeAg-negative adults with chronic hepatitis B virus infection and clinical or virologic resistance to lamivudine: a retrospective, multicenter, nonrandomized, open-label s

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2010.01360.X

21 January 2018

Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to Lamivudine

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2010.01360.X

21 January 2018

Two-year assessment of entecavir resistance in Lamivudine-refractory hepatitis B virus patients reveals different clinical outcomes depending on the resistance substitutions present

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2010.01360.X

21 January 2018

Hepatitis B virus quasispecies susceptibility to entecavir confirms the relationship between genotypic resistance and patient virologic response

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2010.01360.X

21 January 2018

A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2010.01360.X

21 January 2018

The antiviral drug selected hepatitis B virus rtA181T/sW172* mutant has a dominant negative secretion defect and alters the typical profile of viral rebound

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2010.01360.X

21 January 2018

Antiviral drug-resistant HBV: standardization of nomenclature and assays and recommendations for management

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2010.01360.X

21 January 2018

Susceptibility to antivirals of a human HBV strain with mutations conferring resistance to both lamivudine and adefovir.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2010.01360.X

21 January 2018

Features and clinical implications of hepatitis B virus genotypes and mutations in basal core promoter/precore region in 507 Chinese patients with acute and chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2010.01360.X

21 January 2018

Hepatitis B virus genotype and basal core promoter/precore mutations are associated with hepatitis B-related acute-on-chronic liver failure without pre-existing liver cirrhosis

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2010.01360.X

21 January 2018

The rtA194T polymerase mutation impacts viral replication and susceptibility to tenofovir in hepatitis B e antigen-positive and hepatitis B e antigen-negative hepatitis B virus strains

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2010.01360.X

21 January 2018

Chronic hepatitis B: preventing, detecting, and managing viral resistance

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2010.01360.X

21 January 2018

A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2008 update

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2010.01360.X

21 January 2018

SARS-associated coronavirus quasispecies in individual patients

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2010.01360.X

21 January 2018

Genetic variation of SARS coronavirus in Beijing Hospital

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2010.01360.X

21 January 2018

Persistent shedding of viable SARS-CoV in urine and stool of SARS patients during the convalescent phase

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2010.01360.X

21 January 2018

European multicenter evaluation of high-density DNA probe arrays for detection of hepatitis B virus resistance mutations and identification of genotypes

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2010.01360.X

21 January 2018

Sensitivity and accuracy of an updated line probe assay (HBV DR v.3) in detecting mutations associated with hepatitis B antiviral resistance

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2010.01360.X

21 January 2018

Hepatitis B e antigen-negative chronic hepatitis B: natural history and treatment

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2010.01360.X

21 January 2018

Relapse of hepatitis B in HBeAg-negative chronic hepatitis B patients who discontinued successful entecavir treatment: the case for continuous antiviral therapy

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2010.01360.X

21 January 2018

Antiviral resistance and hepatitis B therapy

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2010.01360.X

21 January 2018

Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2010.01360.X

21 January 2018

Adding-on versus switching-to adefovir therapy in lamivudine-resistant HBeAg-negative chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2010.01360.X

21 January 2018

Low risk of adefovir resistance in lamivudine-resistant chronic hepatitis B patients treated with adefovir plus lamivudine combination therapy: two-year follow-up

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2010.01360.X

21 January 2018

Differences of YMDD mutational patterns, precore/core promoter mutations, serum HBV DNA levels in lamivudine-resistant hepatitis B genotypes B and C.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2010.01360.X

21 January 2018

Association of lamivudine-resistant mutational patterns with the antiviral effect of adefovir in patients with chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2010.01360.X

21 January 2018

The L80I substitution in the reverse transcriptase domain of the hepatitis B virus polymerase is associated with lamivudine resistance and enhanced viral replication in vitro

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2010.01360.X

21 January 2018

Evolution of multi-drug resistant hepatitis B virus during sequential therapy

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2010.01360.X

21 January 2018

Selection of a multiple drug-resistant hepatitis B virus strain in a liver-transplanted patient.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2010.01360.X

21 January 2018

Efficacy of entecavir in patients with chronic hepatitis B resistant to both lamivudine and adefovir or to lamivudine alone.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2010.01360.X

21 January 2018

In vitro activity of 2,4-diamino-6-[2-(phosphonomethoxy)ethoxy]-pyrimidine against multidrug-resistant hepatitis B virus mutants

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2010.01360.X

21 January 2018

In vitro characterization of viral fitness of therapy-resistant hepatitis B variants

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2010.01360.X

21 January 2018

Compartmentalization and its implication for peripheral immunologically-competent cells to the liver in patients with HBV-related acute-on-chronic liver failure

1 reference

https://pubmed.ncbi.nlm.nih.gov/21392168

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Circulating and liver resident CD4+CD25+ regulatory T cells actively influence the antiviral immune response and disease progression in patients with hepatitis B

1 reference

https://pubmed.ncbi.nlm.nih.gov/21392168

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Adefovir dipivoxil resistance patterns in patients with lamivudine-resistant chronic hepatitis B.

1 reference

https://pubmed.ncbi.nlm.nih.gov/21392168

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pooled analysis of amino acid changes in the HBV polymerase in patients from four major adefovir dipivoxil clinical trials

1 reference

https://pubmed.ncbi.nlm.nih.gov/21392168

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

In vitro susceptibility of adefovir-associated hepatitis B virus polymerase mutations to other antiviral agents

1 reference

https://pubmed.ncbi.nlm.nih.gov/21392168

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q45368315&oldid=1420814095"